NIAID Investigator Initiated Program Project Applications
ID: 359732Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Small Businesses

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/359732
Timeline
    Description

    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is inviting applications for the Investigator Initiated Program Project Grants aimed at advancing research in areas pertinent to the NIAID mission. This program encourages small businesses to propose innovative projects that explore the biology and pathogenesis of microbes, immune system functions, and the development of vaccines and therapeutics for infectious and immune-mediated diseases. The grant does not require cost-sharing or matching, with an estimated award date set for December 1, 2026, and applications are due by January 25, 2026. For further inquiries, interested applicants can contact Dr. Chelsea Boyd at chelsea.boyd@nih.gov or by phone at 301-761-6664.

    Point(s) of Contact
    Chelsea Boyd, Ph.D. National Institute of Allergy and Infectious Diseases (NIAID)
    (301) 761-6664
    chelsea.boyd@nih.gov
    Files
    No associated files provided.
    Similar Opportunities
    NIAID Resource-Related Research Projects
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "NIAID Resource-Related Research Projects," aimed at supporting investigator-initiated research that develops essential resources for biomedical research. This program encourages small businesses to propose non-hypothesis-driven activities that provide high-quality data, materials, tools, or services relevant to the NIAID mission, which includes areas such as infectious diseases, immune function, and translational research for vaccines and therapeutics. Interested applicants should note that there is no cost-sharing requirement, and the estimated synopsis close date is January 26, 2026, with awards expected to be made by December 1, 2026. For further inquiries, applicants can contact Dr. Chelsea Boyd at chelsea.boyd@nih.gov or by phone at 301-761-6664.
    NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), is offering a funding opportunity for investigator-initiated Resource-Related Research Projects (R24), specifically excluding clinical trials. This initiative aims to enhance existing high-priority research by supporting resources that provide critical data, materials, tools, or services beneficial to the scientific community, particularly in areas related to immunology and infectious diseases. Eligible applicants include a diverse range of institutions, such as higher education and nonprofit organizations, with proposals due by January 7, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-065.html.
    NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (U44 Clinical Trial Required)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIAID SBIR Phase II Clinical Trial Implementation Cooperative Agreement (FON PAR-24-099) aimed at small business concerns proposing investigator-initiated clinical trials that align with the NIAID's research mission. This program supports hypothesis-driven and milestone-driven clinical trials, particularly those classified as high-risk, which may involve unique interventions or the use of licensed products for unapproved indications. The initiative underscores the government's commitment to advancing innovative clinical research to address significant healthcare challenges, with funding of up to $1 million annually available for meritorious applications. Interested applicants must adhere to strict guidelines and submit their applications by the various deadlines, with the first due date on April 12, 2024, and the final deadline on January 13, 2027. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    NIAID Clinical Trial Implementation Cooperative Agreement
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity through the NIAID Clinical Trial Implementation Cooperative Agreement, aimed at supporting high-risk clinical trials and associated mechanistic studies. This program invites small businesses to submit applications for cooperative agreements that facilitate the implementation, conduct, and analysis of investigator-initiated clinical trials, including activities such as training personnel, recruiting subjects, and managing data. The initiative is crucial for advancing research in health-related fields, with no cost-sharing requirements, and is governed by specific federal regulations. Interested applicants can reach out to Dr. Cynthia de la Fuente at cynthia.delafuente@nih.gov or call 240-699-2740 for further information. The estimated synopsis post date is December 5, 2025, with a closing date for applications on February 25, 2026, and an anticipated award date of December 1, 2026.
    Pilot Projects to Enhance the Human Virome Program (R03, Clinical Trials Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a funding opportunity for pilot projects aimed at enhancing the Human Virome Program through a grant titled "Pilot Projects to Enhance the Human Virome Program (R03, Clinical Trials Not Allowed)." This initiative seeks to support small businesses in developing innovative projects that advance the understanding of the healthy human virome, including its characterization, tools, and interactions with the host, while ensuring that proposed projects do not overlap with existing efforts. With an estimated total program funding of $2,000,000 and the expectation of awarding six grants, interested applicants are encouraged to prepare their proposals ahead of the anticipated Notice of Funding Opportunity (NOFO) release, which is expected to be published on September 15, 2025. For further inquiries, potential applicants can contact Amanda Melillo, PhD, at amanda.melillo@nih.gov or by phone at 301-529-7217.
    Impact of Initial Influenza Exposure on Immunity in Infants
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a federal grant opportunity titled "Impact of Initial Influenza Exposure on Immunity in Infants," aimed at advancing research on how influenza infections and vaccinations affect infant and childhood immunity. The initiative seeks to establish and characterize longitudinal cohorts of infants and mother-infant dyads to investigate the influence of initial exposure to influenza antigens on immune responses to subsequent infections and vaccinations. This research is critical for developing durable and broadly protective influenza vaccines. The estimated total program funding is $10 million, with three awards expected, and interested applicants can reach out to Dr. Michelle M. Arnold at michelle.arnold@nih.gov or by phone at 301-761-7324. Key deadlines include an estimated synopsis close date of February 11, 2026, and an estimated award date of December 1, 2026.
    NIAID Clinical Trial Planning Grant (R34 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute of Allergy and Infectious Diseases (NIAID), has announced a funding opportunity for the Clinical Trial Planning Grant (R34), aimed at supporting the planning and preparation necessary for investigator-initiated clinical trials. This grant encourages applications that focus on high-priority research aligned with NIAID's mission, providing funding of up to $150,000 for activities such as protocol development, study team establishment, and regulatory approvals. The opportunity is open to a diverse range of eligible applicants, including educational institutions, nonprofits, and governmental entities, with applications evaluated based on significance, innovation, and the research environment. Interested applicants should note that the application deadline is May 13, 2026, and can find more information at the provided NIH grants link or by contacting NIH Grants Information at grantsinfo@nih.gov.
    Nonhuman Primate Reagent Resource (U24 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is announcing a forthcoming funding opportunity titled "Nonhuman Primate Reagent Resource (U24 Clinical Trial Not Allowed)" aimed at supporting the development, production, and distribution of nonhuman primate-specific immunologic reagents. This initiative, led by the National Institute of Allergy and Infectious Diseases (NIAID), seeks to enhance preclinical research in nonhuman primate models to accelerate advancements in cures, vaccines, and treatments for immune-mediated diseases and emerging infectious diseases. The estimated total program funding is $1,300,000, with one award expected, and applications are anticipated to be solicited starting in late August 2025, with a closing date in late October 2025. Interested applicants can reach out to Dr. Shilpa Kulkarni at shilpa.kulkarni@nih.gov or call 240-747-7365 for further information.
    Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Ancillary Studies to Ongoing Clinical Projects (R01 Clinical Trial Not Allowed)" aimed at supporting research that leverages resources from ongoing clinical studies. This initiative encourages applications for ancillary studies that align with the mission of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), utilizing well-characterized patient cohorts, infrastructure, data, and biological samples from parent studies. With an estimated total program funding of $2 million and an expected four awards, interested small businesses are encouraged to collaborate and develop responsive projects. Key deadlines include an estimated synopsis post date of February 4, 2026, a close date of April 6, 2026, and an anticipated award date of December 4, 2026. For further inquiries, applicants can contact Heiyoung Park, Ph.D., at Heiyoung.Park@nih.gov or by phone at 301-827-5992.
    National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 (P01 Clinical Trial Optional)
    National Institutes of Health
    The National Institutes of Health, through the National Cancer Institute (NCI), invites applications for Program Project grants (P01) aimed at fostering collaborative, multidisciplinary cancer research for the years 2023, 2024, and 2025. Applicants must propose at least three interrelated research projects and an Administrative Core, all centered around a common theme within the expansive field of cancer research, which includes areas such as cancer biology, prevention, diagnosis, treatment, and control. This funding opportunity is crucial for advancing cancer research and enhancing the effectiveness of collaborative efforts, with applications due by May 7, 2026. Interested parties can find more information and application guidelines at the provided link, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.